Trial · NCT07897136
CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia
NCT07897136, Phase 1, Not yet recruiting, Liping Dou
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia. Trials, record NCT07897136. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07897136
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia
- NCT number
- NCT07897136
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 12 participants, estimated
- Lead sponsor
- Liping Dou
- Conditions
- Acute Myeloid Leukemia (AML), Relapsed/Refractory Acute Myeloid Leukemia
- Interventions
- CLL-1-CD70 CAR-T Cell Injection
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | From CAR-T cell infusion through 12 months after infusion. | Number of participants with at least one TEAE following CLL-1/CD70 CAR-T cell infusion, regardless of its relationship to treatment. TEAEs are adverse events that newly occur or worsen after infusion and include serious and non-serious events. Each participant will be counted once, irrespective of the number or type of TEAEs. Severity will be graded using NCI CTCAE v5.0, except that cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded using the ASTCT consensus criteria. Abnormal laboratory, vital sign, physical examination, and electrocardiogram findings will be included when they meet the protocol-defined adverse event criteria. |
| Secondary | Composite Complete Remission Rate (CRc) | At Months 1, 3, 6, 9, and 12 after CAR-T cell infusion. | Percentage of participants meeting the criteria for complete remission (CR), complete remission with partial hematologic recovery (CRh), or complete remission with incomplete hematologic recovery (CRi) at each prespecified assessment time point, according to the European LeukemiaNet (ELN) 2022 response criteria. |
| Secondary | Complete Remission (CR) Rate | At Months 1, 3, 6, 9, and 12 after CAR-T cell infusion. | Percentage of participants meeting the criteria for complete remission at each prespecified assessment time point. CR is defined as bone marrow blasts \<5%, absence of circulating blasts and extramedullary disease, an absolute neutrophil count ≥1.0 × 10\^9/L, and a platelet count ≥100 × 10\^9/L, according to the ELN 2022 response criteria. |
| Secondary | Complete Remission With Partial Hematologic Recovery (CRh) Rate | At Months 1, 3, 6, 9, and 12 after CAR-T cell infusion. | Percentage of participants meeting the criteria for CRh at each prespecified assessment time point. CRh is defined as meeting the morphologic criteria for CR, with an absolute neutrophil count ≥0.5 × 10\^9/L and a platelet count ≥50 × 10\^9/L, without meeting the criteria for CR, according to the ELN 2022 response criteria. |
| Secondary | Complete Remission With Incomplete Hematologic Recovery (CRi) Rate | At Months 1, 3, 6, 9, and 12 after CAR-T cell infusion. | Percentage of participants meeting the criteria for CRi at each prespecified assessment time point. CRi is defined as meeting the morphologic criteria for CR but with incomplete neutrophil or platelet recovery. Participants meeting the criteria for CR or CRh will not be included in this category. Response will be assessed according to the ELN 2022 criteria. |
| Secondary | No Response (NR) Rate | At Months 1, 3, 6, 9, and 12 after CAR-T cell infusion. | Percentage of response-evaluable participants who do not meet the criteria for CR, CRh, CRi, morphologic leukemia-free state (MLFS), or partial remission (PR) at each prespecified assessment time point. Response categories will be determined using the ELN 2022 criteria and the protocol-specified response assessment rules. |
| Secondary | Partial Remission (PR) Rate | At Months 1, 3, 6, 9, and 12 after CAR-T cell infusion. | Percentage of participants meeting the criteria for partial remission at each prespecified assessment time point. PR is defined as meeting all hematologic criteria for CR, with bone marrow blasts reduced to 5%-25% and a reduction of at least 50% from the pretreatment bone marrow blast percentage, according to the ELN 2022 response criteria. |
| Secondary | Morphologic Leukemia-Free State (MLFS) Rate | At Months 1, 3, 6, 9, and 12 after CAR-T cell infusion. | Percentage of participants meeting the criteria for MLFS at each prespecified assessment time point. MLFS is defined as bone marrow blasts \<5%, absence of circulating blasts and extramedullary disease, without requiring hematologic recovery. Bone marrow adequacy and response classification will be assessed according to the ELN 2022 criteria. |
| Secondary | Overall Survival (OS) | From CAR-T cell infusion through 12 months after infusion. | Time from CAR-T cell infusion to death from any cause, reported in months. Participants who have not died will be censored on the date they were last known to be alive. |
| Secondary | Event-Free Survival (EFS) | From CAR-T cell infusion through 12 months after infusion. | Time from CAR-T cell infusion to the first occurrence of a protocol-defined event: failure to achieve CR, CRh, or CRi at the protocol-specified response assessment; hematologic relapse after CR, CRh, or CRi; initiation of new anti-leukemia therapy; or death from any cause, whichever occurs first. Participants without an event will be censored on the date of their last adequate disease assessment. Time will be reported in months. |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07897136
GET https://conductscience.org/api/trials/v1/NCT07897136/registered?page=2